Efficacy and safety of low-dose interleukin 2 for primary Sjögren syndrome: A randomized clinical trial
J He, J Chen, M Miao, R Zhang, G Cheng… - JAMA network …, 2022 - jamanetwork.com
Importance Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated
with dysregulated immune cells, with no efficient therapy. There is a need to study potential
therapeutic approaches. Objective To investigate the efficacy, safety, and immune response
of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS. Design, Setting, and Participants
A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group
superiority design from June 2015 to August 2017. Sixty patients, aged 18 to 70 years, were …
with dysregulated immune cells, with no efficient therapy. There is a need to study potential
therapeutic approaches. Objective To investigate the efficacy, safety, and immune response
of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS. Design, Setting, and Participants
A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group
superiority design from June 2015 to August 2017. Sixty patients, aged 18 to 70 years, were …